These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 111372)

  • 21. Isolation and partial characterization of a tumor-associated antigen of the P815 mastocytoma of DBA/2 mice.
    Al-Rammahy AK; Levy JG; Jackson AL
    J Immunol; 1980 Jan; 124(1):143-50. PubMed ID: 6765966
    [No Abstract]   [Full Text] [Related]  

  • 22. A procedure for the quantitative separation of viable and non-viable P815X2 mastocytoma cells.
    Wilbur SM; Dettman GL
    J Immunol Methods; 1976; 11(3-4):213-23. PubMed ID: 819586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mastocytoma-medicated suppression of mixed lymphocyte culture and mitogen responsiveness.
    DeLustro F; Argyris BF
    Cell Immunol; 1976 Jan; 21(1):177-84. PubMed ID: 129285
    [No Abstract]   [Full Text] [Related]  

  • 24. Altered immunologic responsiveness in mastocytoma-bearing mice.
    Kamo I; Patel C; Friedman H
    J Natl Cancer Inst; 1976 Feb; 56(2):333-8. PubMed ID: 815558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective effect of immune sera against transplantable Moloney virus-induced sarcoma and lymphoma.
    Pearson GR; Redmon LW; Bass LR
    Cancer Res; 1973 Jan; 33(1):171-8. PubMed ID: 4734119
    [No Abstract]   [Full Text] [Related]  

  • 26. Requirement for macrophages in lipopolysaccharide-stimulated mixed thymocyte cultures.
    Ritter J; Lohmann-Matthes ML; Sonntag HG; Fischer H
    Cell Immunol; 1975 Mar; 16(1):153-61. PubMed ID: 123174
    [No Abstract]   [Full Text] [Related]  

  • 27. [A method of detecting the antigenicity of the P-815 mastocytoma in the histocompatible (syngeneic) mouse].
    Bertschmann M; Hess MW; Lüscher EF
    Schweiz Med Wochenschr; 1972 Aug; 102(33):1197-9. PubMed ID: 4626636
    [No Abstract]   [Full Text] [Related]  

  • 28. Reaginic antibody receptors on murine mastocytoma cells.
    Minard P; Levy DA
    J Immunol; 1972 Oct; 109(4):887-90. PubMed ID: 4627514
    [No Abstract]   [Full Text] [Related]  

  • 29. The tumor disappearance reaction: an in vivo effect of a noncytotoxic lymphokine active against tumor cells.
    D'Silva H; Munger W; Cohen MC; Cohen S
    Clin Immunol Immunopathol; 1985 Mar; 34(3):326-32. PubMed ID: 3918820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adsorption of suppressor cell activity on mouse macrophage monolayers.
    Argyris BF; Cotellessa A
    Transplantation; 1979 Nov; 28(5):372-6. PubMed ID: 160634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation of serotype specific antiserum against porcine adenoviruses in mice.
    Kadoi K
    New Microbiol; 1996 Apr; 19(2):179-82. PubMed ID: 8722316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The blocking activity of antisera raised to either tumor antigens or alloantigens in cytotoxicity assays using syngeneic or allogeneic killer cells on the P815 murine mastocytoma target.
    Al-Rammahy AK; Levy JG
    Cell Immunol; 1980 Dec; 56(2):338-46. PubMed ID: 6781763
    [No Abstract]   [Full Text] [Related]  

  • 33. Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y.
    Biddison WE; Palmer JC
    Proc Natl Acad Sci U S A; 1977 Jan; 74(1):329-33. PubMed ID: 402006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor bearer T cells suppress BCG-potentiated antitumor responses II. Characteristics of the efferent phase suppressor.
    Hawrylko E; Mele CA; Stutman O
    Cell Immunol; 1982 Jan; 66(1):139-51. PubMed ID: 6805960
    [No Abstract]   [Full Text] [Related]  

  • 35. Some effects of neuraminidase on the in vitro interactions between spleen and mastocytoma (P815) cells.
    Weiss L; Cudney TL
    Int J Cancer; 1971 Mar; 7(2):187-97. PubMed ID: 4996818
    [No Abstract]   [Full Text] [Related]  

  • 36. Dimeric immunoglobulin E serves as a unit signal for mast cell degranulation.
    Segal DM; Taurog JD; Metzger H
    Proc Natl Acad Sci U S A; 1977 Jul; 74(7):2993-7. PubMed ID: 70786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction of isoantibody and cytotoxic lymphocytes with allogeneic tumor cells.
    Faanes RB; Choi YS
    J Immunol; 1974 Jul; 113(1):279-88. PubMed ID: 4208919
    [No Abstract]   [Full Text] [Related]  

  • 38. Pretreatment of P815 mastocytoma cells with inhibitors of protein synthesis reduces their susceptibility to lysis by cytotoxic thymus-derived lymphocytes.
    D'Angeac AD; Hale AH
    Cell Immunol; 1980 Oct; 55(2):342-54. PubMed ID: 6775821
    [No Abstract]   [Full Text] [Related]  

  • 39. Tumor-associated immunosuppressive factors.
    Friedman H; Secter S; Kamo I; Kateley J
    Ann N Y Acad Sci; 1976; 276():417-30. PubMed ID: 829207
    [No Abstract]   [Full Text] [Related]  

  • 40. Diminished cellular cytotoxicity in mice hyperimmunized prior to skin grafting.
    Sugarbaker PH
    Cell Immunol; 1981 Jan; 57(1):99-113. PubMed ID: 6783318
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.